Bladder cancers frequently exhibit an increased number of epidermal growth factor receptors (EGFR) in comparison to normal urothelium. The EGFR could potentially be a target for toxic conjugates. The aim of our study was to compare the expression of EGFR in metastases with concurrent or primary tumo
Growth factors in bladder cancer
✍ Scribed by M. Liebert
- Publisher
- Springer-Verlag
- Year
- 1995
- Tongue
- English
- Weight
- 927 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0724-4983
No coin nor oath required. For personal study only.
✦ Synopsis
This article is an overview of peptide growth factors, their receptors, and signal-transduction pathways that play a role in bladder cancer. Included in this overview are epidermal growth factor receptor and its ligands, erbB2, fibroblast growth factors, insulin-like growth factor, the transferrin receptor, and transforming growth factor-beta. The use of growth factors or growth factor receptors for diagnostic and therapeutic interventions is also discussed.
📜 SIMILAR VOLUMES
## Abstract Our purpose was to determine the clinical relevance of the detection of circulating tumor cells (CTCs) expressing urothelial and epithelial markers in bladder cancer patients. Sixty‐two patients who presented to Memorial Sloan‐Kettering Cancer Center between July 2000 and September 2001
## Abstract ## BACKGROUND. Cleavage of membrane‐anchored heparin‐binding epidermal growth factor‐like growth factor (proHB‐EGF) yields a soluble HB‐EGF isoform (sHB‐EGF), which is an activating epidermal growth factor receptor (EGFR) ligand and a C‐terminal fragment HB‐EGF‐C acting directly in the